Personalized Medicine Focus HMA Genetics centers its value on enabling physicians to practice personalized medicine by ensuring patients receive the right drug, dose, and timing. This strong patient-outcome narrative can be leveraged to position our pharmacogenomics and CGx testing services to clinicians focused on precision care.

Expansion Opportunities The company is actively exploring a hospital department of pathology (HOPD) model to build on-site LCMS lab capabilities within practices or hospital centers, creating a potential upsell for on-site testing, quicker turnaround, and integrated lab services.

Targeted Customer Sectors Primary focus areas include Pain and Cardiac specialists, Rehab clinics, and Senior Living facilities. These segments align with pharmacogenomics, toxicology, and CGx testing needs, suggesting tailored outreach and bundled service offerings for high-impact facilities.

Regional and Network Reach With executive consultants across multiple states and a history dating back to 2010, HMA Genetics has a broad network that can accelerate partnerships with hospital groups, PCPs, and specialty practices, allowing scaled outreach and rapid referral channels.

Growth and Capabilities Current service mix spans PGx, toxicology, GI and cancer screening, prenatal, wound sequencing, and more, indicating opportunities to cross-sell additional tests to existing physician networks and expand into new high-demand clinical areas as the lab and partnerships mature.